⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523027 | 1.00 | — | — | |
| SCHEMBL24718815 | 1.00 | — | — | |
| SCHEMBL6062287 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL30111345 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL1700412 | 0.98 | — | — | |
| Cadaverine Tartrate SCHEMBL9456630 | 0.84 | GBA1 (0.34) | — | |
| SCHEMBL22574702 | 0.82 | — | — | |
| Hydrochloric Acid SCHEMBL16992674 | 0.80 | SYK (0.31) | — | |
| SCHEMBL30497308 | 0.79 | — | — | |
| SCHEMBL2032083 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12492202-B2 | Macrocyclic PAD4 inhibitors useful as immunosuppressant | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-09 | — | — | US | disclosed |
| EP-4642772-A1 | NLRP3 INFLAMMASOME INHIBITORS | Astrazeneca AB (SE) | 2025-11-05 | — | — | EP | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4486453-A1 | BENZAMIDE COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2025-01-08 | — | — | EP | disclosed |
| EP-4472980-A2 | QUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-118843616-A | Benzamide compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-118660880-A | Quinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2024-09-17 | — | — | CN | disclosed |
| US-20240246964-A1 | SUBSTITUTED 1-ARYL-1’-HETEROARYL COMPOUNDS, SUBSTITUTED 1,1’-BIHETEROARYL COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-25 | — | — | US | disclosed |
| WO-2024153173-A1 | AROMATIC ACETYLENE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-1703402-A | Pyridine derivatives as CB2 receptor modulators | GLAXO GROUP LTD (GB) | 2005-11-30 | — | — | CN | disclosed |
| EP-1565442-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005074939-A1 | COMBINATION OF CB2 MODULATORS AND PDE4 INHIBITORS FOR USE IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| WO-2004029026-A1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2004-04-08 | — | — | WO | disclosed |
| US-4891378-A | CEREBRAL INSUFFICIENCY | BOEHRINGER INGELHEIM ZENTRALE GMBH (DE) | 1990-01-02 | — | — | US | disclosed |
| US-4857528-A | Substituted pyrrolidinones, pharmaceutical compositions and use | BOEHRINGER INGELHEIM KG (DE) | 1989-08-15 | — | — | US | disclosed |
| US-4762832-A | TREATING CEREBRAL INSUFFICIENCY | BOEHRINGER INGELHEIM KG (DE) | 1988-08-09 | — | — | US | disclosed |
| EP-0163260-B1 | NOVEL SUBSTITUTED PYRROLIDINONES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICS | BOEHRINGER INGELHEIM KG (DE) | 1988-08-03 | — | — | EP | disclosed |
| US-4670456-A | 4-Aminocarbonylaminomethyl-1-benzylpyrrolidin-2-ones as nootropic agents and as agents for treating cerebral insufficiency | BOEHRINGER INGELHEIM KG (DE) | 1987-06-02 | — | — | US | disclosed |
| EP-0163260-A1 | Novel substituted pyrrolidinones, process for their manufacture and pharmaceutics | BOEHRINGER INGELHEIM KG (DE) | 1985-12-04 | — | — | EP | disclosed |